Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 204

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma

Open access
Gounder, Mrinal M., Agaram, Narasimhan P., Trabucco, Sally E., Robinson, Victoria, Ferraro, Richard A., Millis, Sherri Z., Krishnan, Anita, Lee, Jessica, Attia, Steven, Abida, Wassim, Drilon, Alexander, Chi, Ping, Angelo, Sandra P. D’, Dickson, Mark A., Keohan, Mary Lou, Kelly, Ciara M., Agulnik, Mark, Chawla, Sant P., Choy, Edwin, Chugh, Rashmi, Meyer, Christian F., Myer, Parvathi A., Moore, Jessica L., Okimoto, Ross A., Pollock, Raphael E., Ravi, Vinod, Singh, Arun S., Somaiah, Neeta, Wagner, Andrew J., Healey, John H., Frampton, Garrett M., Venstrom, Jeffrey M., Ross, Jeffrey S., Ladanyi, Marc, Singer, Samuel, Brennan, Murray F., Schwartz, Gary K., Lazar, Alexander J., Thomas, David M., Maki, Robert G., Tap, William D., Ali, Siraj M., Jin, Dexter X. · 2022 · Nature Communications

Abstract

There are more than 70 distinct sarcomas, and this diversity complicates the development of precision-based therapeutics for these cancers. Prospective comprehensive genomic profiling could overcome this challenge by providing insight into sarcomas’ molecular drivers. Through targeted panel sequencing of 7494 sarcomas representing 44 histologies, we identify highly recurrent and type-specific alterations that aid in diagnosis and treatment decisions. Sequencing could lead to refinement or reassignment of 10.5% of diagnoses. Nearly one-third of patients (31.7%) harbor potentially actionable alterations, including a significant proportion (2.6%) with kinase gene rearrangements; 3.9% have a tumor mutational burden ≥10 mut/Mb. We describe low frequencies of microsatellite instability (<0.3%) and a high degree of genome-wide loss of heterozygosity (15%) across sarcomas, which are not readily explained by homologous recombination deficiency (observed in 2.5% of cases). In a clinically annotated subset of 118 patients, we validate actionable genetic events as therapeutic targets. Collectively, our findings reveal the genetic landscape of human sarcomas, which may inform future development of therapeutics and improve clinical outcomes for patients with these rare cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-022-30496-0

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 204

Metadata

Authors
Gounder, M. M., Agaram, N. P., Trabucco, S. E., Robinson, V., Ferraro, R. A., Millis, S. Z., Krishnan, A., Lee, J., Attia, S., Abida, W., Drilon, A., Chi, P., Angelo, S. P. D., Dickson, M. A., Keohan, M. L., Kelly, C. M., Agulnik, M., Chawla, S. P., Choy, E., Chugh, R., Meyer, C. F., Myer, P. A., Moore, J. L., Okimoto, R. A., Pollock, R. E., Ravi, V., Singh, A. S., Somaiah, N., Wagner, A. J., Healey, J. H., Frampton, G. M., Venstrom, J. M., Ross, J. S., Ladanyi, M., Singer, S., Brennan, M. F., Schwartz, G. K., Lazar, A. J., Thomas, D. M., Maki, R. G., Tap, W. D., Ali, S. M., & Jin, D. X.
Venue
Nature Communications
Published
2022-06-15
Volume
13
Issue
1
Pages
3406-3406
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4282940141
Cited by
204
References
18
FWCI
22.27
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. https://app.cochat.ai/papers/10.1038/s41467-022-30496-0
The paper
Gounder, M. M., Agaram, N. P., Trabucco, S. E., Robinson, V., Ferraro, R. A., Millis, S. Z., Krishnan, A., Lee, J., Attia, S., Abida, W., Drilon, A., Chi, P., Angelo, S. P. D., Dickson, M. A., Keohan, M. L., Kelly, C. M., Agulnik, M., Chawla, S. P., Choy, E., . . . Jin, D. X. (2022). Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nature Communications. https://doi.org/10.1038/s41467-022-30496-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.